Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 57
Filter
1.
Rev. bras. med. esporte ; 29: e2022_0295, 2023. tab, graf
Article in English | LILACS | ID: biblio-1407659

ABSTRACT

ABSTRACT Introduction: Core strength training focuses mainly on the muscle group and neuromuscular system of the central area of the human body to gain strength and stability for complex movements. Studies have reported the effect of core training on high-capacity athletes, but there is still a gap regarding the impacts on physical capacity in running athletes. Objective: To study the effects of strength training on athletes' core and the direct impacts on running quality. Methods: Athletes of the men's running team at the athletic training center of the Institute of Physical Education were core strength trained for 10 to 12 weeks. After the period, physical tests, according to predetermined protocols. The data were compared before, after the intervention, and after statistical treatment, and the findings were discussed according to the scientific literature. Results: After 12 weeks of training, among the five sports skills, there was only a significant difference before and after training of body lateral flexion (right side) (P<0.05), and there was no significant difference before and after training of the other four sport skills (P > 0.05). Conclusions: Through the static and dynamic exercises of core strength training, we can effectively improve the proprioception intervention in body movement so that runners can more accurately control their joints and muscles, ensuring movement and postural accuracy. Level of evidence II; Therapeutic studies - investigation of treatment outcomes.


RESUMO Introdução: O treinamento de força do core concentra-se principalmente no grupo muscular e no sistema neuromuscular da área central do corpo humano, com o propósito de ganho de força e estabilidade para movimentos complexos. Estudos relatam o efeito do treinamento do core em atletas de alta capacidade, porém ainda há uma lacuna quanto aos impactos sobre a capacidade física em atletas de corrida. Objetivo: Estudar os efeitos resultantes do treinamento de força no core dos atletas e os impactos diretos na qualidade da corrida. Métodos: Os atletas da equipe masculina de corrida, no centro de treinamento de atletismo do Instituto de Educação Física, foram treinados com força fundamental por 10 a 12 semanas. Após o período, testes físicos, segundo protocolos pré-determinados, foram executados. Os dados foram comparados antes e após a intervenção, após o tratamento estatístico, os achados foram discutidos segundo a literatura cientifica. Resultados: Após 12 semanas de treinamento, entre as cinco habilidades esportivas, houve apenas diferença significativa antes e depois do treinamento de flexão lateral corporal (lado direito) (P<0,05), e não houve diferença significativa antes e depois do treinamento das outras quatro habilidades esportivas (P > 0,05). Conclusão: Através dos exercícios estáticos e dinâmicos do treinamento de força do core, podemos melhorar efetivamente a intervenção da propriocepção no movimento corporal, para que os corredores possam controlar com mais precisão as articulações e músculos, garantindo a precisão do movimento e postural. Nível de evidência II; Estudos terapêuticos - investigação dos resultados do tratamento.


RESUMEN Introducción: El entrenamiento de la fuerza del core se concentra principalmente en el grupo muscular y en el sistema neuromuscular de la zona central del cuerpo humano, con el fin de ganar fuerza y estabilidad para los movimientos complejos. Los estudios han informado sobre el efecto del entrenamiento del tronco en los atletas de alta capacidad, pero todavía hay un vacío en cuanto a los impactos en la capacidad física en los atletas que corren. Objetivo: Estudiar los efectos resultantes del entrenamiento de fuerza en el core de los atletas y los impactos directos en la calidad de la carrera. Métodos: Los atletas del equipo masculino de atletismo, en el centro de entrenamiento de atletismo del Instituto de Educación Física, fueron entrenados con fuerza central durante 10 a 12 semanas. Tras el periodo, se ejecutaron pruebas físicas, según protocolos predeterminados. Los datos se compararon antes y después de la intervención, tras el tratamiento estadístico, los resultados se discutieron de acuerdo con la literatura científica. Resultados: Después de 12 semanas de entrenamiento, entre las cinco habilidades deportivas, sólo hubo diferencia significativa antes y después del entrenamiento de la flexión lateral del cuerpo (lado derecho) (P<0,05), y no hubo diferencia significativa antes y después del entrenamiento de las otras cuatro habilidades deportivas (P > 0,05). Conclusiones: A través de ejercicios estáticos y dinámicos de entrenamiento de la fuerza del core, podemos mejorar eficazmente la intervención de la propiocepción en el movimiento del cuerpo, de modo que los corredores puedan controlar con mayor precisión las articulaciones y los músculos, asegurando la precisión del movimiento y la postura. Nivel de evidencia II; Estudios terapéuticos - investigación de los resultados del tratamiento.


Subject(s)
Humans , Male , Physical Endurance/physiology , Running/physiology , Athletic Performance/physiology , Endurance Training/methods
2.
Asian Journal of Andrology ; (6): 653-661, 2023.
Article in English | WPRIM | ID: wpr-1009797

ABSTRACT

The final analysis of the phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial showed improvement in overall survival (OS) and other efficacy endpoints with apalutamide plus androgen deprivation therapy (ADT) versus ADT alone in patients with metastatic castration-sensitive prostate cancer (mCSPC). As ethnicity and regional differences may affect treatment outcomes in advanced prostate cancer, a post hoc final analysis was conducted to assess the efficacy and safety of apalutamide in the Asian subpopulation. Event-driven endpoints were OS, and time from randomization to initiation of castration resistance, prostate-specific antigen (PSA) progression, and second progression-free survival (PFS2) on first subsequent therapy or death. Efficacy endpoints were assessed using the Kaplan-Meier method and Cox proportional-hazards models without formal statistical testing and adjustment for multiplicity. Participating Asian patients received once-daily apalutamide 240 mg ( n = 111) or placebo ( n = 110) plus ADT. After a median follow-up of 42.5 months and despite crossover of 47 placebo recipients to open-label apalutamide, apalutamide reduced the risk of death by 32% (hazard ratio [HR]: 0.68; 95% confidence interval [CI]: 0.42-1.13), risk of castration resistance by 69% (HR: 0.31; 95% CI: 0.21-0.46), PSA progression by 79% (HR: 0.21; 95% CI: 0.13-0.35) and PFS2 by 24% (HR: 0.76; 95% CI: 0.44-1.29) relative to placebo. The outcomes were comparable between subgroups with low- and high-volume disease at baseline. No new safety issues were identified. Apalutamide provides valuable clinical benefits to Asian patients with mCSPC, with an efficacy and safety profile consistent with that in the overall patient population.


Subject(s)
Male , Humans , Prostatic Neoplasms/pathology , Androgen Antagonists/therapeutic use , Prostate-Specific Antigen , Castration , Prostatic Neoplasms, Castration-Resistant/drug therapy
3.
Article in Chinese | WPRIM | ID: wpr-991169

ABSTRACT

Glioblastoma(GBM)is a lethal cancer with limited therapeutic options.Dendritic cell(DC)-based cancer vaccines provide a promising approach for GBM treatment.Clinical studies suggest that other immu-notherapeutic agents may be combined with DC vaccines to further enhance antitumor activity.Here,we report a GBM case with combination immunotherapy consisting of DC vaccines,anti-programmed death-1(anti-PD-1)and poly I:C as well as the chemotherapeutic agent cyclophosphamide that was integrated with standard chemoradiation therapy,and the patient remained disease-free for 69 months.The patient received DC vaccines loaded with multiple forms of tumor antigens,including mRNA-tumor associated antigens(TAA),mRNA-neoantigens,and hypochlorous acid(HOCl)-oxidized tumor lysates.Furthermore,mRNA-TAAAs were modified with a novel TriVac technology that fuses TAAs with a destabilization domain and inserts TAAs into full-length lysosomal associated membrane protein-1 to enhance major histo-compatibility complex(MHC)class Ⅰ and Ⅱ antigen presentation.The treatment consisted of 42 DC cancer vaccine infusions,26 anti-PD-1 antibody nivolumab administrations and 126 poly I:C injections for DC infusions.The patient also received 28 doses of cyclophosphamide for depletion of regulatory T cells.No immunotherapy-related adverse events were observed during the treatment.Robust antitumor CD4+and CD8+T-cell responses were detected.The patient remains free of disease progression.This is the first case report on the combination of the above three agents to treat glioblastoma patients.Our results suggest that integrated combination immunotherapy is safe and feasible for long-term treatment in this patient.A large-scale trial to validate these findings is warranted.

4.
Chinese Journal of Oncology ; (12): 29-53, 2022.
Article in Chinese | WPRIM | ID: wpr-935182

ABSTRACT

Prostate cancer (PC) is one of the malignant tumors of the genitourinary system that occurs more often in elderly men. Screening, early diagnosis, and treatment of the PC high risk population are essential to improve the cure rate of PC. The development of the guideline for PC screening and early detection in line with epidemic characteristics of PC in China will greatly promote the homogeneity and quality of PC screening. This guideline was commissioned by the Bureau of Disease Control and Prevention of the National Health Commission. The National Cancer Center of China initiated and convened a working group comprising multidisciplinary experts. This guideline strictly followed the World Health Organization Handbook for Guideline Development and combined the most up-to-date evidence of PC screening, China's national conditions, and practical experience in cancer screening. A total of fifteen detailed evidence-based recommendations were provided with respect to the screening population, technology, procedure management, and quality control in the process of PC screening. This guideline aimed to standardize the practice of PC screening and improve the effectiveness and efficiency of PC prevention and control in China.


Subject(s)
Aged , Humans , Male , Beijing , China/epidemiology , Early Detection of Cancer , Mass Screening , Prostatic Neoplasms/epidemiology
5.
Asian Journal of Andrology ; (6): 161-166, 2022.
Article in English | WPRIM | ID: wpr-928524

ABSTRACT

Ethnicity might be associated with treatment outcomes in advanced prostate cancer. This study aimed to evaluate the efficacy and safety of androgen deprivation therapy (ADT) combined with apalutamide in East Asians with metastatic castration-sensitive prostate cancer (mCSPC). The original phase 3 Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) trial was conducted at 260 sites in 23 countries. This subgroup analysis included patients enrolled in 62 participating centers in China, Japan, and Korea. Radiographic progression-free survival (PFS), time to prostate-specific antigen (PSA) progression, and PSA changes from baseline were compared between groups in the East Asian population. The intent-to-treat East Asian population included 111 and 110 participants in the apalutamide and placebo groups, respectively. The 24-month radiographic PFS rates were 76.1% and 52.3% in the apalutamide and placebo groups, respectively (apalutamide vs placebo: hazard ratio [HR] = 0.506; 95% confidence interval [CI], 0.302-0.849; P = 0.009). Median time to PSA progression was more favorable with apalutamide than placebo (HR = 0.210; 95% CI, 0.124-0.357; P < 0.001). Median maximum percentages of PSA decline from baseline were 99.0% and 73.9% in the apalutamide and placebo groups, respectively. The most common adverse event (AE) was rash in the apalutamide group, with a higher rate than that in the placebo group (37.3% vs 9.1%). The most common grade 3 or 4 AEs were rash (12 [10.9%]) and hypertension (12 [10.9%]) for apalutamide. The efficacy and safety of apalutamide in the East Asian subgroup of the TITAN trial are consistent with the global results.


Subject(s)
Humans , Male , Androgen Antagonists/adverse effects , Exanthema/chemically induced , Asia, Eastern , Prostate-Specific Antigen , Prostatic Neoplasms, Castration-Resistant/pathology , Thiohydantoins/adverse effects
6.
Asian Journal of Andrology ; (6): 50-55, 2022.
Article in English | WPRIM | ID: wpr-928506

ABSTRACT

The purpose of our study is to investigate the prognostic value of phosphatase and tensin homolog on chromosome 10 (PTEN) expression in patients with de novo metastatic castration naïve prostate cancer (mCNPC). A total of 205 patients with mCNPC at Fudan University Shanghai Cancer Center (Shanghai, China) were retrospectively examined. Immunohistochemical staining of PTEN was performed on prostate biopsy samples of these patients. Associations among clinicopathological features, patient survival and PTEN protein expression were analyzed. PTEN loss occurred in 58 of 205 (28.3%) patients. Loss of PTEN was significantly correlated with high metastatic volume (P = 0.017). No association between PTEN expression and Gleason score was observed. Patients with PTEN loss had significantly shorter progression-free survival (PFS, P < 0.001) and overall survival (OS, P < 0.001) compared with patients with intact PTEN expression. Multivariate analysis showed that elevated alkaline phosphatase, high metastatic volume and PTEN loss were independent poor prognostic factors for PFS. The Eastern Cooperative Oncology Group performance status (ECOG PS)#8805; 2 and PTEN loss were independent poor prognostic factors for OS. The adjusted hazard ratio of PTEN loss for PFS and OS was 1.67 (95% confidence interval [CI]: 1.14-2.43, P = 0.008) and 1.95 (95% CI: 1.23-3.10, P = 0.005), respectively. PTEN loss was also significantly associated with shorter PFS (P = 0.025) and OS (P < 0.001) in patients with low-volume metastatic disease. Our data showed that PTEN loss is an independent predictor for shorter PFS and OS in patients with de novo mCNPC.


Subject(s)
Humans , Male , China/epidemiology , PTEN Phosphohydrolase/genetics , Prognosis , Prostatic Neoplasms , Retrospective Studies
7.
China Tropical Medicine ; (12): 1142-2022.
Article in Chinese | WPRIM | ID: wpr-971804

ABSTRACT

@#Abstract: Objective To understand the density changes and seasonal fluctuation of larvae and adults of Aedes albopictus in Hainan Province from 2017 to 2021, and to provide a scientific basis for the prevention and control of dengue fever and other vector-borne diseases in Hainan Province. Methods The Breteau index method was used to monitor the larvae of Aedes mosquitoes, and the breeding sites of all small indoor and outdoor water containers and their larvae was checked and recorded. The adult mosquitoes were monitored by double lamination and light trap. Results A total of 1 962 adult female Aedes albopictus mosquitoes were captured in Hainan Province from 2017 to 2021, accounting for 2.17% of the total captured mosquitoes. There were significant differences in mosquito species composition in different habitats in different years (χ2=312.258, P<0.01). In 2017, the density of mosquitoes in livestock sheds was the highest (9.71 per lamp·night), but the composition ratio of Aedes albopictus was the lowest (1.29%). In 2020, the mosquito density in hospitals was the lowest (2.22 mosquitoes per lamp·night), and in 2019, the proportion of Aedes albopictus in residential areas and hospitals was the highest (3.27% on average).The mosquito density in different habitats was the lowest in 2020. The proportion of Aedes albopictus in residential areas and livestock sheds showed an increasing trend from 2017 to 2021, while the proportion of other habitats showed significant fluctuations. The proportion of Aedes albopictus in hospitals showed an obvious decreasing trend in 2020. From 2017 to 2021, the average mosquito density was 5.97, 4.26, 3.82, 3.39 and 3.68 mosquitoes per lamp·night, respectively, showing a decreasing trend year by year except 2021. Except for 2019, the lure index also showed a decreasing trend, with an average value of 1.5/(hour·net), showing a decreasing trend year by year. From 2017 to 2021, the annual average density of Aedes albopictus in Hainan Province was 0.09 mosquitoes per lamp·night, showing obvious seasonal fluctuation. The Breteau index showed a slow decline from 2017 to 2021, and its annual peak was between June and August, which was 1-2 months later than the peak of adult mosquito density. Conclusions The population density of Aedes albopictus in Hainan shows obvious seasonal characteristics. Mosquito control activities should be carried out according to the seasonal characteristics of mosquitoes to reduce the risk of dengue fever and other infectious diseases.

8.
Asian Journal of Andrology ; (6): 41-46, 2021.
Article in English | WPRIM | ID: wpr-879716

ABSTRACT

Here, we developed a prostate cancer (PCa) risk nomogram including lymphocyte-to-monocyte ratio (LMR) for initial prostate biopsy, and internal and external validation were further conducted. A prediction model was developed on a training set. Significant risk factors with P < 0.10 in multivariate logistic regression models were used to generate a nomogram. Discrimination, calibration, and clinical usefulness of the model were assessed using C-index, calibration plot, and decision curve analysis (DCA). The nomogram was re-examined with the internal and external validation set. A nomogram predicting PCa risk in patients with prostate-specific antigen (PSA) 4-10 ng ml

9.
Asian Journal of Andrology ; (6): 602-607, 2020.
Article in English | WPRIM | ID: wpr-879693

ABSTRACT

The aims of this study were to determine the prognostic value of primary tumor surgery and identify optimal candidates for such surgery among patients with seminoma and distant metastasis at diagnosis. We identified 521 patients with seminoma and distant metastasis at diagnosis between 2004 and 2014 from the Surveillance, Epidemiology, and End Results database. Among these patients, 434 had undergone surgery, whereas 87 had not. The prognostic value of primary tumor surgery was assessed by Kaplan-Meier methods, log-rank analyses, and multivariate Cox's proportional hazards model. Survival curves and forest plots were also plotted. Survival analysis indicated that patients who underwent surgery had a better 5-year overall survival and cancer-specific survival than those who did not. Multivariate analyses demonstrated that primary tumor surgery is an independent prognostic factor for overall survival and cancer-specific survival, along with age at diagnosis, M stage, and marital status. In addition, primary tumor surgery still had considerable prognostic value in the subgroup of patients with lymph node metastasis. Further, forest plots demonstrated that patients with M1a stage, N1 or N2-3 stage, and a younger age at diagnosis (<60 years) may benefit from primary tumor surgery. In conclusion, our findings indicate that primary tumor surgery is correlated with improved survival in patients with seminoma and distant metastasis. Furthermore, primary tumor surgery is an independent prognostic indicator for patients with seminoma and distant metastasis.

10.
J Biosci ; 2019 Jun; 44(2): 1-13
Article | IMSEAR | ID: sea-214384

ABSTRACT

Cervical cancer (CC) is one of the most common female malignancies in the world. Although paclitaxel (PTX) is a criticalchemotherapy agent for the treatment of CC, its treatment outcome is limited by the development of drug resistance. Thepresent study aims to define the role of long non-coding RNA (lncRNA) LINC00511 in the progression of CC with theinvolvement of cell proliferation, apoptosis and resistance to PTX in Hela/PTX cells. CC and adjacent normal tissuesamples were collected from 84 patients with CC, and used to determine LINC0051 expression. PTX-resistant Hela/PTXcell line was constructed, in which LINC0051 was overexpressed or silenced to further investigate the effect of LINC00511on PTX-resistant Hela/PTX cell viability, proliferation, migration, invasion, cell cycle, apoptosis and resistance of CC cellsto PTX. The expression of Bcl-2, Bax, cleaved-caspase-3, matrix metalloproteinase (MMP)-2, MMP-9, multidrug resistance protein 1 (MRP1) and P-glycoprotein (P-GP) was also assessed. High-expression of LINC00511 was found in CCwith its close association with the tumor stage, tumor size and lymph node metastasis. After silencing LINC00511expression, the expression of MRP1, P-GP, Bcl-2, MMP-2 and MMP-9 was decreased, while Bax and cleaved-caspase-3increased with more CC cells arrested at G1 phase. Furthermore, silencing of LINC00511 could suppress cell resistance toPTX, cell viability, cell proliferation, migration and invasion yet promoted cell apoptosis in PTX-resistant Hela/PTX cells.Collectively, our findings demonstrate that silencing of LINC00511 could inhibit CC cell resistance to PTX, cell proliferation, migration and invasion, and promote cell apoptosis in CC. Silencing of LINC00511 provides a novel therapeutictarget for CC.

11.
Article in Chinese | WPRIM | ID: wpr-774579

ABSTRACT

Aesculus chinensis belongs to Hippocastanaceae family,bears medicinal and ornamental values. The oleanane type triterpenoid saponin aescin is regarded as active ingredient and accumulated in seed. In order to understand its molecular basis of the triterpenoid biosynthesis,we used high-throughput sequencing under Illumina Hi Seq 2000 platform to obtain the transcriptome data of seed and flower from A. chinensis to further mine the genes involved in its metabolic pathway. Unigene's de novo splicing was performed using Trinity software; the transcriptome results were annotated with KEGG database to predict the specific pathways of the aescin triterpenoid metabolism. Terpenoid and triterpenoid pathways were found from transcriptome data,and forty seven and twenty seven corresponding genes were uncovered respectively. It was found that there are eight kinds of enzymes related to the terpenoid metabolism pathway precursors and three kinds of enzymes related to the triterpenoid metabolism pathway. In this study,five genes corresponding to triterpene cyclase were analyzed in A. chinensis for the first time,which may participate in the synthesis of triterpenoid. It' s revealed that there were thirty three differential genes associated with the ko00900 and ko00909 pathways by analysis on the difference in transcriptome expression between seeds and flowers; seventeen unigenes were up-regulated and sixteen unigenes were down-regulated in the seeds relative to flowers. In this study, qRT-PCR experiments were used to verify the expression of three key enzyme genes of SQE( Unigene25806),HMGS( Unigene36710),and β-AS( Unigene33291). The results of qRT-PCR were consistent with the transcriptome data. The candidate genes related to triterpenoid saponin aescin synthesis in A. chinensis found in this study can provide theoretical basis for the metabolism synthesis and regulation of aescin.


Subject(s)
Aesculus , Flowers , Gene Expression Profiling , Saponins , Transcriptome , Triterpenes
12.
Frontiers of Medicine ; (4): 3-11, 2019.
Article in English | WPRIM | ID: wpr-771266

ABSTRACT

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide. This malignancy is associated with poor prognosis and high mortality. Novel approaches for prolonging the overall survival of patients with advanced HCC are urgently needed. The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltrating lymphocytes and cytokine-induced killer cells, are more effective than those of traditional strategies. Currently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughs in the treatment of hematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cell lymphoma. Nevertheless, this approach only provides a modest benefit in the treatment of solid tumors. The clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited. Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side effects. In this review, we summarized the current application of ACT, the challenges encountered by CAR-T technology in HCC treatment, and some possible strategies for the future direction of immunotherapeutic research.


Subject(s)
Humans , Adoptive Transfer , Methods , Carcinoma, Hepatocellular , Allergy and Immunology , Therapeutics , Immunotherapy, Adoptive , Methods , Liver Neoplasms , Allergy and Immunology , Therapeutics , Lymphocytes, Tumor-Infiltrating , Cell Biology , Randomized Controlled Trials as Topic , Receptors, Chimeric Antigen , T-Lymphocytes , Cell Biology
13.
National Journal of Andrology ; (12): 329-332, 2019.
Article in Chinese | WPRIM | ID: wpr-816832

ABSTRACT

Objective@#To investigate the attitudes of prostate cancer (PCa) patients towards postoperative penile rehabilitation and their influencing factors.@*METHODS@#Seventy-nine PCa patients underwent radical prostatectomy from January through June 2017 and all received a questionnaire investigation before surgery on IIEF-5 and their attitudes towards postoperative penile rehabilitation. We analyzed the reasons for the patients' rejection of postoperative penile rehabilitation.@*RESULTS@#Totally 56 (71%) of the patients accepted and the other 23 (29%) refused postoperative penile rehabilitation. The factors influencing their attitudes towards penile rehabilitation mainly included age (P = 0.023), income (P = 0.040), tumor stage (P = 0.044), and preoperative sexual activity (P = 0.004). The patients who accepted penile rehabilitation had significantly higher IIEF-5 scores than those who refused it (14.75 ± 0.88 vs 8.48 ± 1.16, P = 0.000 2). During the follow-up period, only 29 (36.7%) of the patients bought the vacuum erection device but not the other 50 (63.3%). The tumor stage (P = 0.004), income (P < 0.01) and preoperative androgen-deprivation therapy (P = 0.039) significantly influenced the patients' decision on the purchase of the device. Relevant admission education achieved a 45% decrease in the number of the patients unwilling to accept penile rehabilitation for worrying about its negative effect on cancer treatment, a 25% decrease in those rejecting penile rehabilitation because of age, and a 20% decrease in those refusing it due to the tumor stage. The cost of treatment was an important reason for the patients' rejection of postoperative penile rehabilitation.@*CONCLUSIONS@#The tumor stage and income are the main factors influencing PCa patients' decision on postoperative penile rehabilitation. Relevant admission education and reduced cost of rehabilitation are important for popularization of postoperative penile rehabilitation in PCa patients.

14.
Asian Journal of Andrology ; (6): 592-597, 2019.
Article in English | WPRIM | ID: wpr-1009713

ABSTRACT

Risk prediction models including the Prostate Health Index (phi) for prostate cancer have been well established and evaluated in the Western population. The aim of this study is to build phi-based risk calculators in a prostate biopsy population and evaluate their performance in predicting prostate cancer (PCa) and high-grade PCa (Gleason score ≥7) in the Chinese population. We developed risk calculators based on 635 men who underwent initial prostate biopsy. Then, we validated the performance of prostate-specific antigen (PSA), phi, and the risk calculators in an additional observational cohort of 1045 men. We observed that the phi-based risk calculators (risk calculators 2 and 4) outperformed the PSA-based risk calculator for predicting PCa and high-grade PCa in the training cohort. In the validation study, the area under the receiver operating characteristic curve (AUC) for risk calculators 2 and 4 reached 0.91 and 0.92, respectively, for predicting PCa and high-grade PCa, respectively; the AUC values were better than those for risk calculator 1 (PSA-based model with an AUC of 0.81 and 0.82, respectively) (all P < 0.001). Such superiority was also observed in the stratified population with PSA ranging from 2.0 ng ml-1to 10.0 ng ml-1. Decision curves confirmed that a considerable proportion of unnecessary biopsies could be avoided while applying phi-based risk calculators. In this study, we showed that, compared to risk calculators without phi, phi-based risk calculators exhibited superior discrimination and calibration for PCa in the Chinese biopsy population. Applying these risk calculators also considerably reduced the number of unnecessary biopsies for PCa.


Subject(s)
Aged , Humans , Male , Asian People/statistics & numerical data , Biopsy , China , Neoplasm Grading , Prostate/pathology , Prostate-Specific Antigen/blood , Prostatic Neoplasms/pathology , Risk Assessment/methods
15.
Asian Journal of Andrology ; (6): 618-622, 2019.
Article in English | WPRIM | ID: wpr-1009704

ABSTRACT

Accumulating evidence suggested that long noncoding RNAs (lncRNAs) possess a potential role in prostate cancer (PCa) diagnosis and prognosis. Rapid biochemical recurrence (BCR) is considered as a sign for clinical recurrence metastasis and PCa-specific mortality. Hence, the aim of the present study was to identify a lncRNA signature that can predict BCR of PCa accurately. Bioinformatics analysis, Kaplan-Meier analyses, Cox regression analyses, and Gene Set Enrichment Analysis (GSEA) were performed in a publicly available database with 499 PCa tissues and 52 matched normal tissues. A signature was identified. All these lncRNAs were differentially expressed between tumor and normal tissues and differentially expressed between high Gleason score and low Gleason score tissues. Furthermore, we developed a seven lncRNAs signature that can predict PCa BCR. Patients classified into low-risk group showed better BCR survival significantly than the patients in the high-risk group (hazard ratio = 0.32, 95% CI: 0.20-0.52, concordance index = 0.63). The area under the curve was 0.68 for BCR. The signature also had good discrimination for BCR in men with Gleason 7 PCa. In conclusion, our results suggest that the seven lncRNAs signature is a new biomarker of BCR and high risk in PCa. In addition, the individual lncRNA warrants further study to uncover the associated mechanisms of PCa progression and the signature could be used to design direct clinical trials for adjuvant therapy.


Subject(s)
Humans , Male , Middle Aged , Biomarkers, Tumor/genetics , Genetic Predisposition to Disease/genetics , Kaplan-Meier Estimate , Neoplasm Grading , Neoplasm Recurrence, Local/genetics , Prognosis , Proportional Hazards Models , Prostatic Neoplasms/genetics , RNA, Long Noncoding/genetics , Risk Assessment
16.
Asian Journal of Andrology ; (6): 131-136, 2019.
Article in English | WPRIM | ID: wpr-1009681

ABSTRACT

This study investigated the clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer (mCRPC). A total of 146 patients with docetaxel-naïve group (103 cases) and docetaxel-resistant group (43 cases) were enrolled from the Shanghai Cancer Center (Shanghai, China) in this retrospective cohort study. The efficacy endpoints were prostate-specific antigen response rate, prostate-specific antigen progression-free survival, clinical/radiographic progression-free survival, and overall survival in response to abiraterone plus prednisone. Significantly higher prostate-specific antigen response rate was found in docetaxel-naïve group (54.4%, 56/103) compared to docetaxel-resistant group (34.9%, 15/43) (P = 0.047). In addition, significantly higher median prostate-specific antigen progression-free survival (14.0 vs 7.7 months, P = 0.005), clinical or radiographic progression-free survival (17.0 vs 12.5 months, P = 0.003), and overall survival (27.0 vs 18.0 months, P = 0.016) were found in docetaxel-naïve group compared to docetaxel-resistant group, respectively. The univariate and multivariate analyses indicated that lower albumin and visceral metastases were independent significant predictors for shorter overall survival. To sum up, our data suggested that abiraterone plus prednisone was efficient in both docetaxel-naïve and docetaxel-resistant Chinese patients. Moreover, higher PSA response rate and longer overall survival were observed in the docetaxel-naïve group, which suggested that abiraterone was more effective for docetaxel- naïve patients than for docetaxel failures.


Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Androstenes/therapeutic use , Antineoplastic Agents, Hormonal/therapeutic use , China , Disease Progression , Disease-Free Survival , Drug Therapy, Combination , Prednisone/therapeutic use , Prostatic Neoplasms, Castration-Resistant/mortality , Retrospective Studies , Survival Rate , Treatment Outcome
17.
Braz. j. med. biol. res ; 52(6): e8132, 2019. tab, graf
Article in English | LILACS | ID: biblio-1001537

ABSTRACT

The aim of this study was to elucidate the concise effects of a traditional herb pair, Curcumae rhizoma-Sparganii rhizoma (CRSR), on uterine leiomyoma (UL) by analyzing transcriptional profiling. The UL rat model was made by intramuscular injection of progesterone and gavage administration of diethylstilbestrol. From 11 weeks of the establishment of the model, rats of the UL+CRSR group were gavaged daily with CRSR (6.67 g/kg). The serum concentrations of progesterone (P) and estradiol (E2) were determined by radioimmunoassay, the uterine index was measured by caliper measurement, and the pathological status was observed by hematoxylin and eosin stain. Gene expression profiling was checked by NimbleGen Rat Gene Expression Microarrays. The results indicated that the uterine mass of UL+CRSR rats was significantly shrunk and serum P and E2 levels significantly reduced compared to UL animals and nearly to the level of normal rats. Results of microarrays displayed the extensive inhibition of CRSR upon the expression of proliferation and deposition of extracellular matrix (ECM)-related genes, and significantly regulated a wide range of metabolism disorders. Furthermore, CRSR extensively regulated key pathways of the UL process, such as MAPK, PPAR, Notch, and TGF-β/Smad. Regulation of the crucial pathways for the UL process and ECM metabolism may be the underlying mechanisms of CRSR treatment. Further studies will provide clear clues for effectively treating UL with CRSR.


Subject(s)
Animals , Female , Rats , Uterine Neoplasms/drug therapy , Plant Extracts/pharmacology , Gene Expression Regulation, Neoplastic/drug effects , Curcuma/chemistry , Rhizome/chemistry , Leiomyoma/drug therapy , Transcription Factors , Uterine Neoplasms/genetics , Uterine Neoplasms/metabolism , Radioimmunoassay , Rats, Sprague-Dawley , Oligonucleotide Array Sequence Analysis , Disease Models, Animal , Leiomyoma/genetics , Leiomyoma/metabolism
18.
Genet. mol. biol ; 41(1): 18-26, Jan.-Mar. 2018. tab, graf
Article in English | LILACS | ID: biblio-892468

ABSTRACT

Abstract This study aimed to determine the association between the polymorphisms and haplotypes in the xeroderma pigmentosum group D (XPD) gene and the risk of pancreatic cancer in the Chinese Han population. SNaPshot was used for genotyping six SNP sites of the XPD gene. Comparisons of the correlations between different genotypes in combination with smoking and the susceptibility to pancreatic cancer were performed. Individual pancreatic cancer risk in patients who carry mutant C alleles (AC, CC, and AC+CC) at rs13181 increased (p < 0.05). Taking non-smoking individuals who carry the AA genotype as a reference, and non-smoking individuals who carry mutant allele C (AC+CC), the risk of pancreatic cancer increased by 3.343 times in individuals who smoked ≥ 20 cigarettes daily, 3.309 times in individuals who smoked ≥ 14 packs per year, 5.011 times in individuals who smoked ≥ 24 packs per year, and 4.013 times in the individuals who smoked ≥ 37 packs per year (P < 0.05). In addition, haplotype analysis revealed that haplotype AGG, which comprised rs13181, rs3916874 and rs238415, was associated with a 1.401-fold increase in pancreatic cancer risk (p < 0.05). We conclude that the polymorphism of XPD Lys751Gln (rs13181) in combination with smoking contributes to increased risk of pancreatic cancer in the Chinese Han population. Haplotype AGG might be a susceptibility haplotype for pancreatic cancer.

19.
Asian Journal of Andrology ; (6): 551-554, 2018.
Article in English | WPRIM | ID: wpr-1009634

ABSTRACT

This study aimed to assess the role of the National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence (BCR) after radical prostatectomy (RP) in Chinese prostate cancer patients. We included a consecutive cohort of 385 patients with prostate cancer who underwent RP at Fudan University Shanghai Cancer Center (Shanghai, China) from March 2011 to December 2014. Gleason grade groups were applied at analysis according to the 2014 International Society of Urological Pathology Consensus. Risk groups were stratified according to the NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer version 1, 2017. All 385 patients were divided into BCR and non-BCR groups. The clinicopathological characteristics were compared using an independent sample t-test, Chi-squared test, and Fisher's exact test. BCR-free survival was compared using the log-rank test and multivariable Cox proportional hazard analysis. During median follow-up of 48 months (range: 1-78 months), 31 (8.05%) patients experienced BCR. The BCR group had higher prostate-specific antigen level at diagnosis (46.54 ± 39.58 ng ml-1 vs 21.02 ± 21.06 ng ml-1, P= 0.001), more advanced pT stage (P = 0.002), and higher pN1 rate (P < 0.001). NCCN risk classification was a significant predictor of BCR (P = 0.0006) and BCR-free survival (P = 0.003) after RP. As NCCN risk level increased, there was a significant decreasing trend in BCR-free survival rate (Ptrend = 0.0002). This study confirmed and validated that NCCN risk classification was a significant predictor of BCR and BCR-free survival after RP.


Subject(s)
Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , China/epidemiology , Cohort Studies , Disease-Free Survival , Follow-Up Studies , Guidelines as Topic , Neoplasm Grading , Neoplasm Recurrence, Local/epidemiology , Prostate-Specific Antigen/analysis , Prostatectomy , Prostatic Neoplasms/surgery , Retrospective Studies , Risk Assessment , Survival Analysis
20.
Asian Journal of Andrology ; (6): 184-188, 2018.
Article in English | WPRIM | ID: wpr-1009553

ABSTRACT

Abiraterone acetate is approved for the treatment of castration-resistant prostate cancer (CRPC); however, its effects vary. An accurate prediction model to identify patient groups that will benefit from abiraterone treatment is therefore urgently required. The Chi model exhibits a good profile for risk classification, although its utility for the chemotherapy-naive group is unclear. This study aimed to externally validate the Chi model and develop a new nomogram to predict overall survival (OS). We retrospectively analyzed a cohort of 110 patients. Patients were distributed among good-, intermediate-, and poor-risk groups, according to the Chi model. The good-, intermediate-, and poor-risk groups had a sample size of 59 (53.6%), 34 (30.9%), and 17 (15.5%) in our dataset, and a median OS of 48.4, 29.1, and 10.5 months, respectively. The C-index of external validation of Chi model was 0.726. Univariate and multivariate analyses identified low hemoglobin concentrations (<110 g l-1), liver metastasis, and a short time interval from androgen deprivation therapy to abiraterone initiation (<36 months) as predictors of OS. Accordingly, a new nomogram was developed with a C-index equal to 0.757 (95% CI, 0.678-0.836). In conclusion, the Chi model predicted the prognosis of abiraterone-treated, chemotherapy-naive patients with mCRPC, and we developed a new nomogram to predict the overall survival of this group of patients with less parameters.


Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Abiraterone Acetate/therapeutic use , Adenocarcinoma/secondary , Alkaline Phosphatase/blood , Androgen Antagonists/therapeutic use , Antineoplastic Agents/therapeutic use , Bone Neoplasms/secondary , Cohort Studies , Kaplan-Meier Estimate , L-Lactate Dehydrogenase/blood , Liver Neoplasms/secondary , Multivariate Analysis , Neoplasm Metastasis , Nomograms , Prognosis , Proportional Hazards Models , Prostatic Neoplasms, Castration-Resistant/pathology , Retrospective Studies , Serum Albumin/metabolism , Survival Rate , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL